Viracta Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial From Both Arms of the Relapsed or Refractory Epstein-Barr Virus-positive Peripheral T-cell Lymphoma Cohort.
Viracta Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial From Both Arms of the Relapsed or Refractory Epstein-Barr Virus-positive Peripheral T-cell Lymphoma Cohort.
Viracta Therapeutics的股價走低。該公司公佈了復發或難治性愛潑斯坦-巴爾病毒陽性外周T細胞淋巴瘤隊列兩個組的關鍵性2期 NAVAL-1 試驗第一階段的主要結果。
Viracta Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial From Both Arms of the Relapsed or Refractory Epstein-Barr Virus-positive Peripheral T-cell Lymphoma Cohort.
Viracta Therapeutics的股價走低。該公司公佈了復發或難治性愛潑斯坦-巴爾病毒陽性外周T細胞淋巴瘤隊列兩個組的關鍵性2期 NAVAL-1 試驗第一階段的主要結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。